137 related articles for article (PubMed ID: 26983700)
21. Characterization of neural cell types expressing peroxiredoxins in mouse brain.
Jin MH; Lee YH; Kim JM; Sun HN; Moon EY; Shong MH; Kim SU; Lee SH; Lee TH; Yu DY; Lee DS
Neurosci Lett; 2005 Jun; 381(3):252-7. PubMed ID: 15896479
[TBL] [Abstract][Full Text] [Related]
22. Does the oxidative stress in chronic obstructive pulmonary disease cause thioredoxin/peroxiredoxin oxidation?
Lehtonen ST; Ohlmeier S; Kaarteenaho-Wiik R; Harju T; Pääkkö P; Soini Y; Kinnula VL
Antioxid Redox Signal; 2008 Apr; 10(4):813-9. PubMed ID: 18179358
[TBL] [Abstract][Full Text] [Related]
23. Analysis of peroxiredoxin decreasing oxidative stress in hypertensive aortic smooth muscle.
Lee CK; Kim HJ; Lee YR; So HH; Park HJ; Won KJ; Park T; Lee KY; Lee HM; Kim B
Biochim Biophys Acta; 2007 Jul; 1774(7):848-55. PubMed ID: 17556052
[TBL] [Abstract][Full Text] [Related]
24. DNA adduct 8-hydroxydeoxyguanosine, a novel putative marker of prognostic significance in ovarian carcinoma.
Karihtala P; Soini Y; Vaskivuo L; Bloigu R; Puistola U
Int J Gynecol Cancer; 2009 Aug; 19(6):1047-51. PubMed ID: 19820366
[TBL] [Abstract][Full Text] [Related]
25. Oxidative/nitrosative stress and peroxiredoxin 2 are associated with grade and prognosis of human renal carcinoma.
Soini Y; Kallio JP; Hirvikoski P; Helin H; Kellokumpu-Lehtinen P; Kang SW; Tammela TL; Peltoniemi M; Martikainen PM; Kinnula VL
APMIS; 2006 May; 114(5):329-37. PubMed ID: 16725008
[TBL] [Abstract][Full Text] [Related]
26. Expression of thioredoxin system and related peroxiredoxin proteins is associated with clinical outcome in radiotherapy treated early stage breast cancer.
Woolston CM; Storr SJ; Ellis IO; Morgan DA; Martin SG
Radiother Oncol; 2011 Aug; 100(2):308-13. PubMed ID: 21641069
[TBL] [Abstract][Full Text] [Related]
27. CD8+ T-cell content in diagnostic lymph nodes measured by flow cytometry is a predictor of survival in follicular lymphoma.
Wahlin BE; Sander B; Christensson B; Kimby E
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):388-97. PubMed ID: 17255259
[TBL] [Abstract][Full Text] [Related]
28. Peroxiredoxin VI in human respiratory system.
Chuchalin AG; Novoselov VI; Shifrina ON; Soodaeva SK; Yanin VA; Barishnikova LM
Respir Med; 2003 Feb; 97(2):147-51. PubMed ID: 12587965
[TBL] [Abstract][Full Text] [Related]
29. Identification of MUM1 as a prognostic immunohistochemical marker in follicular lymphoma using computerized image analysis.
Xerri L; Bachy E; Fabiani B; Canioni D; Chassagne-Clément C; Dartigues-Cuilléres P; Charlotte F; Brousse N; Rousselet MC; Foussard C; Brice P; Feugier P; Morschhauser F; Sonet A; Olive D; Salles G;
Hum Pathol; 2014 Oct; 45(10):2085-93. PubMed ID: 25149549
[TBL] [Abstract][Full Text] [Related]
30. Prognostic implications of histologic grade and intensity of Bcl-2 expression in follicular lymphomas undergoing rituximab-containing therapy.
Maeshima AM; Taniguchi H; Nomoto J; Miyamoto K; Fukuhara S; Munakata W; Maruyama D; Kim SW; Watanabe T; Kobayashi Y; Tobinai K; Tsuda H
Hum Pathol; 2013 Nov; 44(11):2529-35. PubMed ID: 23916290
[TBL] [Abstract][Full Text] [Related]
31. Decreased Expression of Peroxiredoxin in Patients with Ovarian Endometriosis Cysts.
Yu H; Hao JM; Li X; Li F; Li J; Li L
Arch Med Res; 2020 Oct; 51(7):670-674. PubMed ID: 32564961
[TBL] [Abstract][Full Text] [Related]
32. Aberrant expression of peroxiredoxin subtypes in neurodegenerative disorders.
Krapfenbauer K; Engidawork E; Cairns N; Fountoulakis M; Lubec G
Brain Res; 2003 Mar; 967(1-2):152-60. PubMed ID: 12650976
[TBL] [Abstract][Full Text] [Related]
33. CD23 expression in follicular lymphoma: clinicopathologic correlations.
Olteanu H; Fenske TS; Harrington AM; Szabo A; He P; Kroft SH
Am J Clin Pathol; 2011 Jan; 135(1):46-53. PubMed ID: 21173123
[TBL] [Abstract][Full Text] [Related]
34. The Relevance of Mammalian Peroxiredoxins to the Gametogenesis, Embryogenesis, and Pregnancy Outcomes.
Li L
Reprod Sci; 2017 Jun; 24(6):812-817. PubMed ID: 27624309
[TBL] [Abstract][Full Text] [Related]
35. Expression of bcl-6 and CD10 protein is associated with longer overall survival and time to treatment failure in follicular lymphoma.
Bilalovic N; Blystad AK; Golouh R; Nesland JM; Selak I; Trinh D; Torlakovic E
Am J Clin Pathol; 2004 Jan; 121(1):34-42. PubMed ID: 14750238
[TBL] [Abstract][Full Text] [Related]
36. The thioredoxin antioxidant system.
Lu J; Holmgren A
Free Radic Biol Med; 2014 Jan; 66():75-87. PubMed ID: 23899494
[TBL] [Abstract][Full Text] [Related]
37. Expression and prognostic evaluation of oxidative stress markers in an immunohistochemical study of B-cell derived lymphomas.
Pasanen AK; Kuitunen H; Haapasaari KM; Karihtala P; Kyllönen H; Soini Y; Turpeenniemi-Hujanen T; Kuittinen O
Leuk Lymphoma; 2012 Apr; 53(4):624-31. PubMed ID: 21929285
[TBL] [Abstract][Full Text] [Related]
38. Dysregulation of redox-state-regulating enzymes in melanocytic skin tumours and the surrounding microenvironment.
Hintsala HR; Soini Y; Haapasaari KM; Karihtala P
Histopathology; 2015 Sep; 67(3):348-57. PubMed ID: 25627040
[TBL] [Abstract][Full Text] [Related]
39. Synaptic NMDA receptor activity boosts intrinsic antioxidant defenses.
Papadia S; Soriano FX; Léveillé F; Martel MA; Dakin KA; Hansen HH; Kaindl A; Sifringer M; Fowler J; Stefovska V; McKenzie G; Craigon M; Corriveau R; Ghazal P; Horsburgh K; Yankner BA; Wyllie DJ; Ikonomidou C; Hardingham GE
Nat Neurosci; 2008 Apr; 11(4):476-87. PubMed ID: 18344994
[TBL] [Abstract][Full Text] [Related]
40. Follicular lymphoma in early stages: high risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients.
Plancarte F; López-Guillermo A; Arenillas L; Montoto S; Giné E; Muntañola A; Ferrer A; Villamor N; Bosch F; Colomo L; Balaguer O; Campo E; Montserrat E
Eur J Haematol; 2006 Jan; 76(1):58-63. PubMed ID: 16343272
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
